Developing Tools to Discover New Therapeutic Agents (2019)

Dr. Roger Ashmus from Simon Fraser University shared ongoing research in synthetic chemistry for studying enzymes related to Parkinson's disease. He concentrated on GC Ace, its link to alpha-synuclein aggregation, and the challenges in developing fluorescence quench probes for live cell imaging of GC Ace activity, including solubility and probe turnover.

The webinar highlighted the creation of a probe to monitor GCS activity within live cells and its use in a drug discovery high-throughput screen. The process from target identification to clinical studies was outlined, focusing on basic research, and presented potential compounds as activators or inhibitors of GCS activity, offering new therapeutic targets for Parkinson's disease.

View the video slides accompanying this presentation by clicking here.

**Disclaimer: These sessions are designed to provide general education and are not intended for individual advice and/or clinical care. The information conveyed in this recording was accurate at the time of presentation.**